BCL2 and lung carcinoma: Furthermore, the anticancer activity of jorunnamycin A targeting on CSCs is evidenced by the sensitizing effect on cisplatin-induced apoptosis in CSC-enriched lung cancer cells via upregulation of p53 tumor suppressor protein and decreased expression of anti-apoptosis Bcl-2 (Figure 11).